# Ixico PLC

## Pages

- [Neuroscience & Biomarker Solutions for CNS Clinical Trials.](https://ixico.com/index.md): IXICO is a neuroscience company delivering AI-powered neuroimaging and biomarker analysis for CNS clinical trials. Trusted by global pharma and biotech to accelerate drug development.
- [Imaging Biomarker Analysis for CNS Clinical Trials | IXICO](https://ixico.com/services/imaging-biomarkers/index.md): IXICO provides expert imaging biomarker analysis for CNS clinical trials across Alzheimer's, Parkinson's, Huntington's, and other rare neurological diseases. Precision insights to support drug development.
- [Radiological Reads for CNS Clinical Trials | IXICO](https://ixico.com/services/imaging-biomarkers/radiological-reads/index.md): IXICO delivers expert radiological reads for CNS clinical trials, including safety and efficacy reads. Independent, standardised imaging assessments to support regulatory submissions.
- [IXICO Share Price | Live Investor Information](https://ixico.com/investors/share-price/index.md): View the latest IXICO share price and stock market data. Access live and historical price information for IXICO's AIM-listed shares.
- [Company Documents | IXICO Investor Resources](https://ixico.com/investors/investor-resources/company-documents/index.md): Download IXICO's latest company documents including annual reports, prospectuses, and regulatory filings for shareholders and institutional investors.
- [AIM Rule 26 Disclosures | IXICO  ](https://ixico.com/investors/governance/aim-rule-26/index.md): Access IXICO's AIM Rule 26 disclosures, including corporate governance information, directors' details, and regulatory compliance documents for AIM investors.
- [Website Privacy Policy | IXICO](https://ixico.com/privacy-policy/website/index.md): Read IXICO's website privacy policy to learn how we handle personal data collected through our site, including cookies and analytics, in line with UK GDPR.
- [News](https://ixico.com/news-and-resources/news/index.md)
- [Global clinical trial contract wins in Alzheimer’s Disease  and Friedreich’s Ataxia ](https://ixico.com/news-and-resources/news/global-clinical-trial-contract-wins-in-alzheimers-disease-and-friedreichs-ataxia/index.md)
- [Neuroimaging Biomarkers for Friedreich's Ataxia: A Cross-Sectional Analysis of the TRACK-FA Study](https://ixico.com/news-and-resources/publications/neuroimaging-biomarkers-for-friedreich-ataxia-a-cross-sectional-analysis-of-the-track-fa-study/index.md): Discover the largest neuroimaging study on Friedreich's ataxia, TRACK-FA. Learn about significant differences in brain and spinal cord development between patients and controls, including young children. Explore key findings and the potential of imaging biomarkers in clinical trials.
- [Parkinson's Disease: Unveiling the Promise of Neuromelanin Sensitive Imaging](https://ixico.com/news-and-resources/webinars/parkinsons-disease-unveiling-the-promise-of-neuromelanin-sensitive-imaging/index.md)
- [Huntington's Disease: Your Imaging Analysis & Operations Solutions Partner ](https://ixico.com/news-and-resources/downloads/huntingtons-disease-your-imaging-analysis-and-operations-solutions-partner/index.md)
- [Why partnerships are the promising pathway for Alzheimer’s breakthroughs](https://ixico.com/news-and-resources/blog/why-partnerships-are-the-promising-pathway-for-alzheimers-breakthroughs/index.md)
- [Mission](https://ixico.com/company/index.md#mission)
- [Submit RFP](https://ixico.com/contact-us/submit-rfp/index.md)
- [Alzheimer's Disease Biomarkers | IXICO](https://ixico.com/therapeutic-areas/alzheimers-disease/index.md): IXICO supports Alzheimer's disease clinical trials with precision neuroimaging and biomarker analysis. Accelerate AD drug development and diagnostics with our CNS expertise.
- [AI-Driven Insights](https://ixico.com/platform/index.md#insights-derived-from-imaging-biomarker-data)
- [About IXICO | Neuroimaging & Biomarker Experts Since 2004](https://ixico.com/company/index.md): Learn about IXICO's mission to transform neurological disease research. Since 2004, we've delivered leading neuroimaging and biomarker insights to advance CNS therapies.
- [Clinical Trial Imaging Management | IXICO](https://ixico.com/services/trial-management/index.md): IXICO delivers expert clinical trial imaging management for CNS studies. From site qualification to data analysis and delivery, we support every stage of your trial.
- [Volumetric MRI Biomarker Analysis for CNS Trials | IXICO](https://ixico.com/services/imaging-biomarkers/volumetric-mri/index.md): IXICO is a recognised leader in precision volumetric MRI analysis for CNS clinical trials. Quantify brain structure changes to support drug efficacy and disease progression endpoints.
- [Global Site Support | Clinical Trial Imaging Assistance | IXICO](https://ixico.com/contact-us/global-site-support/index.md): IXICO provides dedicated global site support for clinical trial imaging. IXICO operates a 24/7 support system at every trial site, worldwide.
- [Financial Calendar | IXICO Key Investor Dates](https://ixico.com/investors/investor-resources/financial-calendar/index.md): View IXICO's financial calendar for key dates including results announcements, AGMs, and investor events. Stay informed on IXICO 's corporate schedule.
- [Our Board](https://ixico.com/investors/governance/our-board/index.md)
- [Business Partner & Supplier Privacy Notice | IXICO  ](https://ixico.com/privacy-policy/business-partner-and-supplier-privacy-notice/index.md): Read IXICO's privacy notice for business partners and suppliers. Learn how we handle personal data in our commercial and supply chain relationships under UK GDPR.
- [Scientific Publications](https://ixico.com/news-and-resources/publications/index.md)
- [IXICO and Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership for the Transformative Bio-Hermes-002 Study](https://ixico.com/news-and-resources/news/ixico-and-global-alzheimers-platform-foundation-announces-strategic-collaboration-and-partnership-for-the-transformative-bio-hermes-002-study/index.md)
- [Comparison of two natural history studies as part of the HD-IH consortium: a use case for historical external control group matching in clinical trials](https://ixico.com/news-and-resources/publications/comparison-of-two-natural-history-studies-as-part-of-the-hd-ih-consortium-a-use-case-for-historical-external-control-group-matching-in-clinical-trials/index.md)
- [Neurological Disorders - Harmonisation of Imaging in Clinical Trials](https://ixico.com/news-and-resources/webinars/neurological-disorders-harmonisation-of-imaging-in-clinical-trials/index.md)
- [Your Imaging Analysis & Operations Experts in Alzheimer’s Disease Clinical Research](https://ixico.com/news-and-resources/downloads/your-imaging-analysis-and-operations-experts-in-alzheimers-disease-clinical-research/index.md)
- [The New Research Developments Driving Precision Care in Parkinson’s Disease ](https://ixico.com/news-and-resources/blog/the-new-research-developments-driving-precision-care-in-parkinsons-disease/index.md)
- [About IXICO](https://ixico.com/company/index.md#about-ixico)
- [Huntington's Disease Neuroimaging & Biomarker Analytics | IXICO](https://ixico.com/therapeutic-areas/huntingtons-disease/index.md): IXICO provides specialist neuroimaging, biomarker, and diagnostics analysis for Huntington's disease clinical trials. Explore our HD research and imaging capabilities.
- [Platform Features](https://ixico.com/platform/index.md#platform-highlights)
- [IXI Platform | AI Imaging - AI-Powered Neuroimaging Technology](https://ixico.com/platform/index.md): Discover IXICO's IXI™ Platform - a proprietary AI-enabled neuroimaging ecosystem built for CNS clinical trials. Integrating algorithms, global infrastructure, and deep neuroscience expertise.
- [Neuroimaging Data Analytics & Biomarker Data Analysis | IXICO](https://ixico.com/services/data-analytics/index.md): IXICO's data analytics services deliver secure, compliant neuroimaging and biomarker insights for CNS clinical trials, powered by AI and purpose-built technology.
- [PET & SPECT Imaging Services for CNS Clinical Trials | IXICO](https://ixico.com/services/imaging-biomarkers/pet-and-spect/index.md): IXICO provides expert PET and SPECT imaging analysis for CNS clinical trials. Precision biomarker quantification to support drug development across neurological diseases.
- [Corporate Governance & Oversight | IXICO  ](https://ixico.com/investors/governance/oversight/index.md): Explore IXICO's approach to corporate governance and board oversight. Learn how we maintain accountability, transparency, and integrity as an AIM-listed company.
- [Site Management & Terms of Use | IXICO  ](https://ixico.com/privacy-policy/site-management-and-terms-of-use/index.md): Read IXICO's site management privacy policy and terms of use. Understand the legal framework governing access to and use of the IXICO website.
- [Webinars](https://ixico.com/news-and-resources/webinars/index.md)
- [Revenues anticipated to be ahead of expectations for the  year ending 30 September 2025](https://ixico.com/news-and-resources/news/revenues-anticipated-to-be-ahead-of-expectations-for-the-year-ending-30-september-2025/index.md)
- [Fully automatic detection and quantification of new white matter lesions using deep learning](https://ixico.com/news-and-resources/publications/fully-automatic-detection-and-quantification-of-new-white-matter-lesions-using-deep-learning/index.md)
- [Advancing Alzheimer's Research: enhancing clinical trial diversity and relevant imaging considerations](https://ixico.com/news-and-resources/webinars/advancing-alzheimers-research-enhancing-clinical-trial-diversity-and-relevant-imaging-considerations/index.md)
- [Executing a Multi-Arm Phase 1 Alzheimer’s Disease Global Clinical Trial with Clinilabs and IXICO](https://ixico.com/news-and-resources/downloads/executing-a-multi-arm-phase-1-alzheimers-disease-global-clinical-trial-with-clinilabs-and-ixico/index.md)
- [Imaging of Neurodegeneration within the NIA-AA Research Framework: The ‘N’ in the AT(N) Scheme](https://ixico.com/news-and-resources/blog/imaging-of-neurodegeneration-within-the-nia-aa-research-framework-the-n-in-the-atn-scheme/index.md)
- [IXI™ Platform](https://ixico.com/index.md)
- [Governance](https://ixico.com/investors/index.md#governance)
- [Investor Presentations | IXICO  ](https://ixico.com/investors/investor-resources/investor-presentations/index.md): View the latest investor presentations from IXICO. Access strategy updates, financial highlights, and business overviews for shareholders and analysts.
- [Parkinson's Disease Biomarkers | IXICO](https://ixico.com/therapeutic-areas/parkinsons-disease/index.md): IXICO supports Parkinson's disease clinical trials with advanced neuroimaging and biomarker analysis. Leverage our CNS expertise to advance PD drug development.
- [Platform Evolution](https://ixico.com/platform/index.md#platform-evolution)
- [Neuroimaging & Biomarker Services for CNS Clinical Trials](https://ixico.com/services/index.md): IXICO provides end-to-end neuroimaging, biomarker, and diagnostic iCRO services for CNS clinical trials, from imaging operations and data analytics to post-marketing surveillance.
- [Post-Marketing Surveillance | Neurological Imaging](https://ixico.com/services/post-marketing/index.md): IXICO supports post-marketing surveillance with neuroimaging analytics for CNS therapies after regulatory approval.
- [Advanced MRI Biomarker Analytics for CNS Trials | IXICO](https://ixico.com/services/imaging-biomarkers/advanced-mri/index.md): IXICO offers advanced MRI biomarker analysis including DTI, fMRI, and perfusion imaging for CNS clinical trials. Unlock deeper neuroimaging insights to support drug development.
- [Investor Videos | IXICO Management Presentations](https://ixico.com/investors/investor-resources/investor-videos/index.md): Watch the latest investor videos from IXICO, including management presentations, strategy updates, and results briefings for shareholders and analysts.
- [Contacts & Advisers | IXICO Investor Relations](https://ixico.com/investors/governance/contacts-and-advisers/index.md): Find contact details for IXICO's key advisers including its nominated adviser, broker, auditors, and legal counsel for investor relations purposes.
- [Shareholder Privacy Notice | IXICO](https://ixico.com/privacy-policy/shareholder-privacy-notice/index.md): View IXICO's shareholder privacy notice. Understand how we process personal data relating to shareholders and investors in compliance with data protection law.
- [Downloads](https://ixico.com/news-and-resources/downloads/index.md)
- [Biomarkers and imaging in Alzheimer’s disease: Understanding Amyloid and Tau within the ATN Framework](https://ixico.com/news-and-resources/blog/biomarkers-and-imaging-in-alzheimers-disease-understanding-amyloid-and-tau-within-the-atn-framework/index.md)
- [Multiple Sclerosis – Advancing treatment through imaging biomarkers](https://ixico.com/news-and-resources/webinars/multiple-sclerosis-advancing-treatment-through-imaging-biomarkers/index.md)
- [Neuroimaging to Facilitate Clinical Trials in Huntington’s Disease: Current Opinion from the EHDN Imaging Working Group - IOS Press](https://ixico.com/news-and-resources/publications/neuroimaging-to-facilitate-clinical-trials-in-huntingtons-disease-current-opinion-from-the-ehdn-imaging-working-group-ios-press/index.md)
- [IXICO assists first FDA clearance of new Alzheimer’s Disease  blood based diagnostic biomarker](https://ixico.com/news-and-resources/news/ixico-assists-first-fda-clearance-of-new-alzheimers-disease-blood-based-diagnostic-biomarker/index.md)
- [The Power of Neuroimaging](https://ixico.com/company/index.md#the-power-of-neuroimaging)
- [Investor Resources](https://ixico.com/investors/index.md#investor-resources)
- [Multiple Sclerosis Neuroimaging & Biomarker Analytics | IXICO](https://ixico.com/therapeutic-areas/multiple-sclerosis/index.md): IXICO supports multiple sclerosis clinical trials with expert neuroimaging and biomarker analytics. Drive MS drug development with precision MRI and AI-powered insights.
- [Consultancy](https://ixico.com/services/consultancy/index.md)
- [Therapeutic Areas | CNS & Neurological Disease Imaging | IXICO](https://ixico.com/therapeutic-areas/index.md): IXICO specialises in neuroimaging across key CNS therapeutic areas including Alzheimer's, Huntington's, and Parkinson's disease. Explore our expertise.
- [RNS News](https://ixico.com/investors/investor-resources/rns-news/index.md)
- [A Quick Guide to Imaging Analysis & Operations Essentials in Alzheimer’s Disease Clinical Research](https://ixico.com/news-and-resources/blog/a-quick-guide-to-imaging-analysis-and-operations-essentials-in-alzheimers-disease-clinical-research/index.md)
- [Parkinson's Disease - The road ahead for imaging biomarkers](https://ixico.com/news-and-resources/webinars/parkinsons-disease-the-road-ahead-for-imaging-biomarkers/index.md)
- [Volumetric change across the different Stages of the Huntington’s disease Integrated Staging System (HD-ISS) defined at baseline](https://ixico.com/news-and-resources/publications/comparison-of-local-amyloid-pet-uptake-patterns-between-black-and-white-participants-in-the-gap-bio-hermes-study/index.md)
- [Interim results for six months ending 31 March 2025 ](https://ixico.com/news-and-resources/news/interim-results-for-six-months-ending-31-march-2025/index.md)
- [Your Partner in Parkinson's Disease Imaging Analysis and Operations Solutions](https://ixico.com/news-and-resources/downloads/parkinsons-disease-imaging-analysis-and-operations-solutions/index.md)
- [Our Customers | Pharma & Biotech Partners | IXICO](https://ixico.com/company/customers/index.md): IXICO partners with leading pharmaceutical and biotech companies worldwide. Discover how we support CNS clinical trials with neuroimaging expertise and analytics.
- [Rare Neurological Disease Neuroimaging Services | IXICO](https://ixico.com/therapeutic-areas/therapeutic-areas-2/index.md): IXICO delivers neuroimaging and biomarker solutions for rare neurological diseases including Spinocerebellar Ataxia (SCA) and Friedreich's Ataxia (FA). Explore our CNS capabilities.
- [News & Resources ](https://ixico.com/news-and-resources/index.md): Stay up to date with the latest news, publications, and resources from IXICO, covering neuroimaging science, clinical trial innovation, and company updates.
- [Recent Scientific Publications | IXICO Neuroimaging Research](https://ixico.com/therapeutic-areas/recent-scientific-publications/index.md): Explore IXICO's latest scientific publications in neuroimaging and biomarker research. Access peer-reviewed papers supporting CNS drug development across key therapeutic areas.
- [Regulatory News Alert | IXICO Investor Updates](https://ixico.com/investors/investor-resources/share-price-email-alert/index.md): Sign up for regulatory news email alerts. Stay informed on the latest updates from IXICO directly to your inbox.
- [Blog](https://ixico.com/news-and-resources/blog/index.md)
- [Innovation Trends in AD Research –the shift to increasingly individualised trial design, therapeutics and care.](https://ixico.com/news-and-resources/blog/innovation-trends-in-ad-research-may-2025/index.md)
- [Huntington's Disease: The present and future of imaging biomarkers ](https://ixico.com/news-and-resources/webinars/huntingtons-disease-the-present-and-future-of-imaging-biomarkers/index.md)
- [Erosion of The Supratentorial White Matter Reference for Increased Power in Longitudinal Amyloid PET ](https://ixico.com/news-and-resources/publications/erosion-of-the-supratentorial-white-matter-reference-for-increased-power-in-longitudinal-amyloid-pet/index.md)
- [Half-year Trading update - FY2025](https://ixico.com/news-and-resources/news/half-year-trading-update-fy2025/index.md)
- [Partnerships | Neuroimaging, Technology and Research Collaborations | IXICO](https://ixico.com/company/partnerships/index.md): IXICO collaborates with leading technology and healthcare partners to advance neuroimaging and biomarker science. Explore our strategic partnerships.
- [Investor Relations | IXICO - AIM-Listed Neuroscience Company](https://ixico.com/investors/index.md): Access investor information for IXICO an AIM-listed neuroscience technology company. Find reports, regulatory updates, and shareholder resources.
- [Shareholder Information | IXICO  ](https://ixico.com/investors/investor-resources/shareholder-info/index.md): Find key shareholder information for IXICO, including share capital details, major shareholders, and regulatory disclosures for investors.
- [Business Development Director](https://ixico.com/company/careers/business-development-director/index.md)
- [Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis ](https://ixico.com/news-and-resources/blog/imagingadvancing-biomarker-research-for-alzheimers-disease-diagnosis/index.md)
- [Gene therapy for the CNS: The roles of neuroimaging](https://ixico.com/news-and-resources/webinars/gene-therapy-for-the-cns-the-roles-of-neuroimaging/index.md)
- [Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants](https://ixico.com/news-and-resources/publications/association-between-regional-volume-change-and-clinical-change-in-huntingtons-disease-hd-iss-stage-2-and-stage-3-participants/index.md)
- [Contract Wins in Alzheimer’s and Huntington’s Disease](https://ixico.com/news-and-resources/news/contract-wins-in-alzheimers-and-huntingtons-disease/index.md)
- [Leadership Team](https://ixico.com/company/index.md#advisors)
- [Contact IXICO | Get in Touch with Our Neuroimaging Experts](https://ixico.com/contact-us/index.md): Get in touch with the IXICO team. Whether you're a pharma partner, investor, or job seeker, we're here to help. Contact us today.
- [Discussing research multi-biomarker advances in Alzheimer’s Disease at ADPD 2025](https://ixico.com/news-and-resources/blog/discussing-research-multi-biomarker-advances-in-alzheimers-disease-at-adpd-2025/index.md)
- [Alzheimer’s disease: emerging neuroimaging techniques in clinical trials](https://ixico.com/news-and-resources/webinars/alzheimers-disease-emerging-neuroimaging-techniques-in-clinical-trials/index.md)
- [A Deep Learning Framework For Clinical Trial Enrichment in Alzheimer’s Disease](https://ixico.com/news-and-resources/publications/a-deep-learning-framework-for-clinical-trial-enrichment-in-alzheimers-disease/index.md)
- [Huntington’s Disease consortium further validates IXICO’s AI imaging platform](https://ixico.com/news-and-resources/news/huntingtons-disease-consortium-further-validates-ixicos-ai-imaging-platform/index.md)
- [Advisors](https://ixico.com/company/index.md#advisors)
- [Terms & Conditions | IXICO ](https://ixico.com/terms-and-conditions/index.md): Review IXICO's website terms and conditions. Understand the rules and guidelines governing your use of the IXICO website and its content.
- [International Women's Day 2025](https://ixico.com/news-and-resources/blog/international-womens-day-2025/index.md)
- [Getting neuroimaging right — How to succeed in neurodegenerative clinical trials](https://ixico.com/news-and-resources/webinars/getting-neuroimaging-right-how-to-succeed-in-neurodegenerative-clinical-trials/index.md)
- [Comparison of amyloid positivity and global cortical SUVR between black and white non-Hispanic participants in the GAP Bio-Hermes study](https://ixico.com/news-and-resources/publications/comparison-of-amyloid-positivity-and-global-cortical-suvr-between-black-and-white-non-hispanic-participants-in-the-gap-bio-hermes-study/index.md)
- [Commercial agreement with PETNET Solutions Inc, a Siemens Healthineers Company](https://ixico.com/news-and-resources/news/commercial-agreement-with-petnet-solutions-inc-a-siemens-healthineers-company/index.md)
- [Careers](https://ixico.com/company/careers/index.md)
- [Privacy Policy | IXICO  ](https://ixico.com/privacy-policy/index.md): Read IXICO's privacy policy to understand how we collect, use, and protect your personal data in line with UK GDPR and data protection regulations.
- [Alzheimer's Disease: The Role of Cutting-Edge Neuroimaging Techniques](https://ixico.com/news-and-resources/blog/alzheimers-disease-the-role-of-cutting-edge-neuroimaging-techniques/index.md)
- [Clinical and Imaging Biomarkers in Parkinsonian Syndromes](https://ixico.com/news-and-resources/webinars/clinical-and-imaging-biomarkers-in-parkinsonian-syndromes/index.md)
- [A convolutional neural network-based framework for imaging biomarkers in MS - white matter hyperintensity & brain region volumes ](https://ixico.com/news-and-resources/publications/a-convolutional-neural-network-based-framework-for-imaging-biomarkers-in-ms-white-matter-hyperintensity-and-brain-region-volumes-ectrims-2023/index.md)
- [US Client Clinical Trial Contract Win](https://ixico.com/news-and-resources/news/us-client-clinical-trial-contract-win-dec-2024/index.md)
- [Director of Neuroscience Medical Affairs](https://ixico.com/company/careers/director-neuroscience-medical-affairs/index.md): Join IXICO as Director of Neuroscience Medical Affairs. Lead scientific strategy and stakeholder engagement across CNS clinical trial programmes at a global neuroimaging CRO.
- [Cookie Policy](https://ixico.com/cookie-policy/index.md)
- [How Data, Imaging & AI Are Transforming MS Clinical Research](https://ixico.com/news-and-resources/blog/how-data-imaging-and-ai-are-transforming-ms-clinical-research/index.md)
- [A deep-learning based framework for brain-atrophy measurement - AD/PD 2021](https://ixico.com/news-and-resources/webinars/a-deep-learning-based-framework-for-brain-atrophy-measurement/index.md)
- [Automated VMAT2 \[18F\] AV-133 PET analysis in Parkinson's disease](https://ixico.com/news-and-resources/publications/automated-vmat2-18f-av-133-pet-analysis-in-parkinsons-disease/index.md)
- [Appointment of CEO - Bram Goorden](https://ixico.com/news-and-resources/news/appointment-of-ceo-bram-goorden/index.md)
- [Using AI To Advance Imaging Operations & Analysis in Phase III Clinical Trials for Alzheimer’s](https://ixico.com/news-and-resources/webinars/advancing-imaging-operations-and-analysis-in-alzheimers-disease-late-stage-clinical-trialsg-post/index.md)
- [Fully automatic deep-learning based segmentation of hippocampal subfields from standard resolution T1W MRI in Alzheimer’s disease](https://ixico.com/news-and-resources/publications/fully-automatic-deep-learning-based-segmentation-of-hippocampal-subfields-from-standard-resolution-t1w-mri-in-alzheimers-disease/index.md)
- [ IXICO to support on Global Alzheimer's Platform Foundation's Bio-Hermes 2 trial](https://ixico.com/news-and-resources/news/global-alzheimers-platform-foundation-bio-hermes-2-trial/index.md)
- [Associate Image Analyst](https://ixico.com/company/careers/associate-image-analyst/index.md)
- [CHDI's 17th Annual Therapeutics Conference: The Future of Huntington's Research](https://ixico.com/news-and-resources/blog/chdis-17th-annual-therapeutics-conference-the-future-of-huntingtons-research/index.md): Huntington’s Disease research has been through a challenging time. CHDI gave an up-to-date HD review, from the molecular level to late-stage clinical trials.
- [MIUA 2020: Transfer Learning for Brain Segmentation: Pre-task Selection and Data Limitations](https://ixico.com/news-and-resources/webinars/miua-2020/index.md)
- [MR Imaging in Ataxias Consensus Recommendations by the Ataxia Global Initiative Working Group on MRI Biomarkers](https://ixico.com/news-and-resources/publications/mr-imaging-in-ataxias-consensus-recommendations-by-the-ataxia-global-initiative-working-group-on-mri-biomarkers/index.md)
- [Life Molecular Imaging Collaboration Agreement](https://ixico.com/news-and-resources/news/life-molecular-imaging-collaboration-agreement/index.md)
- [GAP-Net Site Optimization Conference 2022: Event Review](https://ixico.com/news-and-resources/blog/gap-net-site-optimization-conference-2022-event-review/index.md): This year’s GAP Foundation conference was a collaborative event with many interesting discussions on issues related to research in Alzheimer’s Disease.
- [Free Water Imaging in Alzheimer's Disease](https://ixico.com/news-and-resources/webinars/free-water/index.md)
- [Validation of IXIQ.Ai+gBSI : an automated framework for caudate atrophy measurement in Huntington’s disease](https://ixico.com/news-and-resources/publications/validation-of-ixiq-ai-gbsi-an-automated-framework-for-caudate-atrophy-measurement-in-huntingtons-disease/index.md)
- [Imeka Collaboration Agreement](https://ixico.com/news-and-resources/news/imeka-collaboration-agreement/index.md)
- [Sitemap](https://ixico.com/sitemap/index.md)
- [IXI Platform Delivery Lead](https://ixico.com/company/careers/ixi-platform-delivery-lead/index.md)
- [IXICO & GAP Foundation: Alzheimer’s & The Bio-Hermes Study](https://ixico.com/news-and-resources/blog/ixico-and-gap-foundation-alzheimers-and-the-bio-hermes-study/index.md)
- [ Using AI to optimize Tau PET Imaging for Alzheimer’s Disease Clinical Development](https://ixico.com/news-and-resources/webinars/using-ai-to-optimize-tau-pet-imaging-for-alzheimers-disease-clinical-development/index.md)
- [Validation of a Jacobian AI-based method to measure cerebellar volume changes in multiple system atrophy](https://ixico.com/news-and-resources/publications/validation-of-a-jacobian-ai-based-method-to-measure-cerebellar-volume-changes-in-multiple-system-atrophy/index.md)
- [The impact of diversity on Alzheimer's disease clinical trial design](https://ixico.com/news-and-resources/news/the-impact-of-diversity-on-alzheimers-disease-clinical-trial-design/index.md)
- [Associate Director/Director Corporate Development & Partnership](https://ixico.com/company/careers/associate-directordirector-corporate-development-and-partnership/index.md)
- [Recruitment Privacy Notice | IXICO Careers](https://ixico.com/company/careers/recruitment-privacy-notice/index.md): Read IXICO's recruitment privacy notice. Learn how we collect, use, and protect the personal data of job applicants in line with GDPR requirements.
- [Discover IXIQ.Ai | IXICO's AI-Based Brain Segmentation Platform](https://ixico.com/news-and-resources/blog/discover-ixiq-ai-ixicos-ai-based-brain-segmentation-platform/index.md): IXIQ.Ai is our new AI-based platform for brain segmentation. Robin Wolz explains its exciting potential for clinical trial and healthcare applications.
- [Huntington’s Disease Image Harmonization Consortium secures new member and funding to complete large-scale analysis of brain changes using IXIQ.Ai](https://ixico.com/news-and-resources/news/huntingtons-disease-image-harmonization-consortium-secures-new-member-and-funding-to-complete-large-scale-analysis-of-brain-changes-using-ixiq-ai/index.md)
- [Deep-learning methods for enrichment of Alzheimer’s Disease clinical trials using MRI and PET](https://ixico.com/news-and-resources/publications/deep-learning-methods-for-enrichment-of-alzheimers-disease-clinical-trials-using-mri-and-pet/index.md)
- [Alzheimer’s Landscapes: Comorbidities, Novel Targets, and Imaging Through the Neuroradiologist’s Lens](https://ixico.com/news-and-resources/webinars/alzheimers-landscapes-comorbidities-novel-targets-and-imaging-through-the-neuroradiologists-lens/index.md)
- [Interview with IXICO & GAP Foundation ](https://ixico.com/news-and-resources/blog/interview-with-ixico-and-gap-foundation/index.md)
- [Call to Action – New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease](https://ixico.com/news-and-resources/news/call-to-action-new-consortium-will-use-artificial-intelligence-technology-to-conduct-large-scale-analysis-of-brain-changes-in-huntingtons-disease/index.md)
- [Amyloid PET centiloid: impact of calibration and processing steps](https://ixico.com/news-and-resources/publications/amyloid-pet-centiloid-impact-of-calibration-and-processing-steps/index.md)
- [ Advancing AD Clinical Trials Through Blood-Based Biomarkers & Amyloid PET Webinar](https://ixico.com/news-and-resources/webinars/advancing-ad-clinical-trials-through-blood-based-biomarkers-and-amyloid-pet-webinar/index.md)
- [Engagement in New Consortium in Huntington’s disease](https://ixico.com/news-and-resources/news/engagement-in-new-consortium-in-huntingtons-disease/index.md)
- [Application of fully automatic Hippocampal sub-field segmentation volumes to standard resolution T1 MR Imaging in Alzheimer’s disease](https://ixico.com/news-and-resources/publications/application-of-fully-automatic-hippocampal-sub-field-segmentation-volumes-to-standard-resolution-t1-mr-imaging-in-alzheimers-disease/index.md)
- [Endpoint selection in Huntington’s disease trials: how neuroimaging advances drive better outcomes](https://ixico.com/news-and-resources/webinars/endpoint-selection-in-huntingtons-disease-clinical-trials-and-how-advances-in-neuroimaging-can-drive-better-trial-outcomes/index.md)
- [IXICO hails the introduction of IXIQ.Ai, its new brain imaging technology ](https://ixico.com/news-and-resources/news/first-contract-award-from-new-imaging-master-vendor-agreement-with-top-5-global-cro/index.md)
- [MDS 2022 Poster – An automated AI-based framework for putamen volume measurement in Multiple System Atrophy](https://ixico.com/news-and-resources/publications/mds-2022-poster-an-automated-ai-based-framework-for-putamen-volume-measurement-in-multiple-system-atrophy/index.md)
- [Advancing Clinical And Imaging Biomarkers In Parkinson’s Disease Research](https://ixico.com/news-and-resources/blog/advancing-clinical-and-imaging-biomarkers-in-parkinsons-disease-research/index.md)
- [Going for growth: IXICO primed to solve the challenge of increased clinical trial complexity through AI advances](https://ixico.com/news-and-resources/news/going-for-growth-ixico-primed-to-solve-the-challenge-of-increased-clinical-trial-complexity-through-ai-advances/index.md)
- [EHDN Imaging Working Group Presentation on new HD-IH Consortium](https://ixico.com/news-and-resources/publications/ehdn-imaging-working-group-presentation-on-new-hd-ih-consortium/index.md)
- [Understanding Imaging in Parkinson’s Disease Trials: From Eligibility to Efficacy](https://ixico.com/news-and-resources/webinars/understanding-imaging-in-parkinsons-disease-trials-from-eligibility-to-efficacy/index.md)
- [Overcoming Imaging Challenges To Advance Huntington’s Disease Research](https://ixico.com/news-and-resources/blog/overcoming-imaging-challenges-to-advance-huntingtons-disease-research/index.md)
- ["As clinical trials become more complex, we're seeing the \[use of\] medical imaging increasing" says Giulio Cerroni in S&P Global Market Intelligence interviewNew Blog Post](https://ixico.com/news-and-resources/news/as-clinical-trials-become-more-complex-were-seeing-the-use-of-medical-imaging-increasing-says-giulio-cerroni-in-s-and-p-global-market-intelligence-interviewnew-blog-post/index.md)
- [AD/PD 2021 Poster - Automatic segmentation using deep learning for the hippocampus](https://ixico.com/news-and-resources/publications/adpd-2021-poster-automatic-segmentation-using-deep-learning-for-the-hippocampus/index.md)
- [Where Vascular Disease and Alzheimer’s Meet: Shared Pathways to Cognitive Decline ](https://ixico.com/news-and-resources/webinars/where-vascular-disease-and-alzheimers-meet-shared-pathways-to-cognitive-decline/index.md)
- [Revolutionizing Analytics: The Role of Deep-Learning AI in CNS Clinical Trials](https://ixico.com/news-and-resources/blog/revolutionizing-analytics-the-role-of-deep-learning-ai-in-cns-clinical-trials/index.md)
- [AMYPAD's interview with Katherine Gray, IXICO's associate director of technology](https://ixico.com/news-and-resources/news/amypads-interview-with-katherine-gray-ixicos-associate-director-of-technologynew-blog-post/index.md)
- [AD/PD 2021 Poster - An adaptive step detection algorithm for waist-worn wearable devices: A feasibility study in older adults](https://ixico.com/news-and-resources/publications/adpd-2021-poster-an-adaptive-step-detection-algorithm-for-waist-worn-wearable-devices-a-feasibility-study-in-older-adults/index.md)
- [AAIC 2020 Day 3 Summary ](https://ixico.com/news-and-resources/blog/aaic-2020-day-3-summary/index.md)
- [BGF investment fund's Paul Stevens: IXICO has “market leading position" & “impressive commercial traction”](https://ixico.com/news-and-resources/news/bgf-investment-funds-paul-stevens-ixico-has-market-leading-position-and-impressive-commercial-traction/index.md)
- [AD/PD 2021 Poster - Added value of wearable sensors for fall risk assessment in an older adult group](https://ixico.com/news-and-resources/publications/adpd-2021-poster/index.md)
- [AAIC 2020 Day Two Summary](https://ixico.com/news-and-resources/blog/aaic-2020-day-one-summary-2/index.md)
- [Investors chronicle: 'IXICO upgrades guidance again'](https://ixico.com/news-and-resources/news/investors-chronicle-ixico-upgrades-guidance-again/index.md)
- [IEEE International Conference on Healthcare Informatics (ICHI) 2020 Poster](https://ixico.com/news-and-resources/publications/ieee-international-conference-on-healthcare-informatics-ichi-2020-poster/index.md)
- [AAIC 2020 Day One Summary](https://ixico.com/news-and-resources/blog/aaic-2020-day-one-summary/index.md)
- [Investors chronicle: 'Profit from artificial intelligence in neuroscience'](https://ixico.com/news-and-resources/news/investors-chronicle-profit-from-artificial-intelligence-in-neuroscience/index.md)
- [Huntington Study Group (HSG) 2020 Poster](https://ixico.com/news-and-resources/publications/huntington-study-group-hsg-2020-poster/index.md)
- [The rise of digital health in the times of COVID-19](https://ixico.com/news-and-resources/blog/digital-health-covid-19/index.md)
- [Huntington Study Group (HSG) 2020 Poster](https://ixico.com/news-and-resources/publications/huntington-study-group-hsg-2020-poster-2/index.md)
- [IXICO wins "CRO Provider of the Year 2025" at the Precision Medicine Awards](https://ixico.com/news-and-resources/news/ixico-wins-cro-provider-of-the-year-2025-at-the-precision-medicine-awards/index.md)
- [Alzheimer's Association International Conference (AAIC) Poster 2020](https://ixico.com/news-and-resources/publications/alzheimers-association-international-conference-aaic-poster-2020/index.md)
- [A Quick Guide to Imaging Analysis & Operations Essentials in Parkinson’s Disease Clinical Research](https://ixico.com/news-and-resources/blog/a-quick-guide-to-imaging-analysis-and-operations-essentials-in-parkinsons-disease-clinical-research/index.md)
- [New blood based biomarker contract win and  contract extension worth a total of £1.2 million](https://ixico.com/news-and-resources/news/new-blood-based-biomarker-contract-win-and-contract-extension-worth-a-total-of-1-2-million/index.md)
- [Alzheimer's Association International Conference (AAIC) Poster 2020 ](https://ixico.com/news-and-resources/publications/alzheimers-association-international-conference-aaic-poster-2/index.md)
- [Trading update for the year ended 30 September 2025](https://ixico.com/news-and-resources/news/trading-update-for-the-year-ended-30-september-2025/index.md)
- [Advancing AD Trials: Integrating Plasma Biomarkers and Imaging for Precision Enrolment](https://ixico.com/news-and-resources/blog/advancing-ad-trials-integrating-plasma-biomarkers-and-imaging-for-precision-enrolment/index.md)
- [Medical Image Understanding and Analysis (MIUA) Publication 2020](https://ixico.com/news-and-resources/publications/medical-image-understanding-and-analysis-miua-publication-2020/index.md)
- [Capital Markets Day 2025](https://ixico.com/news-and-resources/news/capital-markets-day-2025/index.md)
- [Exploring how GLP-1 Drugs and vascular biomarkers are shaping Alzheimer’s Disease clinical trial design](https://ixico.com/news-and-resources/blog/exploring-how-glp-1-drugs-and-vascular-biomarkers-are-shaping-alzheimers-disease-clinical-trial-design/index.md)
- [Schizophrenia International Research Society (SIRS) 2020 Poster](https://ixico.com/news-and-resources/publications/sirs-2020-congress/index.md)
- [Global Phase 3 Clinical Trial Contract Win](https://ixico.com/news-and-resources/news/global-phase-3-clinical-trial-contract-win/index.md)
- [The Emergence of Neuromelanin-Sensitive Imaging in Parkinson’s Disease  Clinical Trials](https://ixico.com/news-and-resources/blog/the-emergence-of-neuromelanin-sensitive-imaging-in-parkinsons-clinical-trials/index.md)
- [Quantitative amyloid PET in Alzheimer’s disease: the AMYPAD prognostic and natural history study](https://ixico.com/news-and-resources/publications/amyloid-pet-alzheimers-disease-amypad/index.md)
- [IXICO strengthens Scientific Advisory Board with two prominent global Alzheimer’s Disease and vascular experts](https://ixico.com/news-and-resources/news/ixico-strengthens-scientific-advisory-board-with-two-prominent-global-alzheimers-disease-and-vascular-experts/index.md)
- [Advancing Amyloid Assessment in PET Imaging: Integrating AI with Quantitative Metrics](https://ixico.com/news-and-resources/blog/advancing-amyloid-assessment-in-pet-imaging-integrating-ai-with-quantitative-metrics/index.md)
- [Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Poster 2020](https://ixico.com/news-and-resources/publications/adpd-poster-2020/index.md)
- [Financial Results for year ended 30 September 2025 and Notice of AGM](https://ixico.com/news-and-resources/news/financial-results-for-year-ended-30-september-2025-and-notice-of-agm/index.md)
- [Multi-biomarker assessment to better understand clinical dementia symptoms](https://ixico.com/news-and-resources/blog/multi-biomarker-assessment-to-better-understand-clinical-dementia-symptoms/index.md)
- [Advances in Alzheimer’s and Parkinson’s Therapies (AAT-ADPD) Poster 2020](https://ixico.com/news-and-resources/publications/advances-in-alzheimers-and-parkinsons-therapies-aat-adpd-poster/index.md)
- [IXICO appoints Chief Commercial Officer to accelerate business development activity and broaden US footprint ](https://ixico.com/news-and-resources/news/ixico-appoints-chief-commercial-officer-to-accelerate-business-development-activity-and-broaden-us-footprint/index.md)
- [Advancing a Multimodal Future for Alzheimer’s Disease Diagnosis](https://ixico.com/news-and-resources/blog/advancing-a-multimodal-future-for-alzheimers-disease-diagnosis/index.md)
- [CHDI Poster 2020](https://ixico.com/news-and-resources/publications/cdhi/index.md)
- [c.£1.5 million contract extension on global Phase 2 clinical trial  ](https://ixico.com/news-and-resources/news/c-1-5-million-contract-extension-on-global-phase-2-clinical-trial/index.md)
- [Advancing HD Clinical Trials with Automated Imaging: What the Latest Research Shows](https://ixico.com/news-and-resources/blog/advancing-hd-clinical-trials-with-automated-imaging-what-the-latest-research-shows/index.md)
- [Human Amyloid Imaging (HAI) Poster 2020](https://ixico.com/news-and-resources/publications/the-impact-of-automatic-tau-pet-processing-on-uptake-variability-and-power-analysis-in-ad/index.md)
- [IXICO further validates the automation capabilities of  its IXI™ neuroimaging technology platform](https://ixico.com/news-and-resources/news/ixico-further-validates-the-automation-capabilities-of-its-ixi-neuroimaging-technology-platform/index.md)
- [From Information to Intelligence: New Platform Identity Explained](https://ixico.com/news-and-resources/blog/from-information-to-intelligence-bram-goodren-ceo-of-ixico-explains-the-new-identity-of-the-ixi-platform-and-why-it-matters/index.md)
- [Human Amyloid Imaging (HAI) Poster 2020](https://ixico.com/news-and-resources/publications/human-amyloid-imaging-conference/index.md)
- [IXICO and Medidata collaborate to create an advanced neuroimaging clinical trials platform      ](https://ixico.com/news-and-resources/news/ixico-and-medidata-collaborate-to-create-an-advanced-neuroimaging-clinical-trials-platform/index.md)
- [Neuromelanin MRI: An Early, Longitudinal Biomarker for Parkinson’s Disease](https://ixico.com/news-and-resources/blog/neuromelanin-mri-an-early-longitudinal-biomarker-for-parkinsons-disease/index.md)
- [Clinical Trials on Alzheimer’s Disease (CTAD) Poster 2019](https://ixico.com/news-and-resources/publications/clinical-trials-on-alzheimers-disease-ctad-2019-poster-2/index.md): Classifying cognitively healthy subjects from mild cognitive impaired and Alzheimer's disease patients using Tau-PET: The role of spatial resolution and PET pre-processing
- [IXICO RELEASES LATEST VERSION OF AI-DRIVEN NEUROIMAGING TECHNOLOGY PLATFORM](https://ixico.com/news-and-resources/news/ixico-releases-latest-version-of-ai-driven-neuroimaging-technology-platform/index.md)
- [White matter hyperintensities: A precision neurology tool for Alzheimer’s patient stratification and improved trial sensitivity? ](https://ixico.com/news-and-resources/blog/white-matter-hyperintensities-a-precision-neurology-tool-for-alzheimers-patient-stratification-and-improved-trial-sensitivity/index.md)
- [Clinical Trials on Alzheimer’s Disease (CTAD) Poster 2019](https://ixico.com/news-and-resources/publications/clinical-trials-on-alzheimers-disease-ctad-2017-poster/index.md)
- [Interim results for six months ending 31 March 2026. Continued strong revenue and order book growth.](https://ixico.com/news-and-resources/news/ixico-plc/index.md)
- [Beyond Diagnosis: 8 MRI and PET Biomarkers Shaping Alzheimer's Clinical Trials](https://ixico.com/news-and-resources/blog/pet-mri-biomarkers-alzheimers-clinical-trials/index.md): A practical guide to 8 PET and MRI biomarkers – from structural MRI to amyloid, tau and FDG PET – used in Alzheimer’s disease clinical trials
- [Clinical Trials on Alzheimer’s Disease (CTAD) Poster 2019](https://ixico.com/news-and-resources/publications/clinical-trials-on-alzheimers-disease-ctad-2017-poster-2/index.md): A pipeline for automated diffusion MRI analysis: overview and application to the study of Alzheimer’s Disease
- [IXICO reports strong H1 revenue growth as Alzheimer’s trial demand accelerates](https://ixico.com/news-and-resources/news/ixico-reports-strong-h1-revenue-growth-as-alzheimers-trial-demand-accelerates/index.md)
- [Company Annual Report 2019](https://ixico.com/news-and-resources/publications/company/index.md)
- [IXICO EXPANDS RESEARCH COLLABORATIONS IN ALZHEIMER’S AND PARKINSON’S DISEASE](https://ixico.com/news-and-resources/news/ixico-expands-research-collaborations-in-alzheimers-and-parkinsons-disease/index.md)
- [Huntington Study Group (HSG) Annual Meeting Poster 2019](https://ixico.com/news-and-resources/publications/hsg-poster-nov-2019/index.md): A Fully Automatic Pipeline for Estimation of Putamen and Caudate Volume
- [IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](https://ixico.com/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/index.md)
- [Spinocerebellar Ataxias (SCA) Global Conference 2019 Poster](https://ixico.com/news-and-resources/publications/sca-2019/index.md): Development of a fully automated method for MRI volumetry in ataxia
- [IXICO announces 28% expected revenue growth for FY26](https://ixico.com/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/index.md)
- [Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Poster](https://ixico.com/news-and-resources/publications/ctad-2017-poster/index.md): Extracting digital biomarkers of sleep from 3-axis accelerometry using Deep Learning
- [IXICO announces two contracts in Alzheimer's disease worth £1.5 million](https://ixico.com/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/index.md)
- [AI-Driven Recruitment for Alzheimer’s Disease Clinical Trials: A Pilot Analysis on the A4 Study Dataset](https://ixico.com/news-and-resources/publications/ai-driven-recruitment-for-alzheimers-disease-clinical-trials-a-pilot-analysis-on-the-a4-study-dataset/index.md)
- [Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET](https://ixico.com/news-and-resources/publications/agreement-between-amyloid-status-prediction-from-visual-read-suvr-thresholding-and-ai-based-interpretation-of-amyloid-pet/index.md)
- [Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography](https://ixico.com/news-and-resources/publications/biomarkers-in-patients-with-clinical-signs-of-mild-cognitive-impairment-or-mild-alzheimers-disease-but-without-amyloid-deposits-on-positron-emission-tomography/index.md)
- [Interchangeability of blood-based biomarkers and PET to identify Alzheimer's disease pathology](https://ixico.com/news-and-resources/publications/interchangeability-of-blood-based-biomarkers-and-pet-to-identify-alzheimers-disease-pathology/index.md)
- [Further validation of IXI technology platform automation capabilities](https://ixico.com/news-and-resources/publications/further-validation-of-ixi-technology-platform-automation-capabilities/index.md)
- [Improving Neuromelanin-sensitive MRI measurement ](https://ixico.com/news-and-resources/publications/improving-neuromelanin-sensitive-mri-measurement/index.md)
- [Neuromelanin-Sensitive MRI of the Substantia Nigra: Comparing TSE and MT-GRE Contrast](https://ixico.com/news-and-resources/publications/contrast-ratio-assessment-of-the-substantia-nigra-in-neuromelanin-sensitive-mri/index.md): ESMRMB 2026 poster comparing TSE and MT-GRE neuromelanin-sensitive MRI of the substantia nigra. MT-GRE showed consistently higher substantia nigra contrast, a promising imaging biomarker for Parkinson's disease clinical trials.